ArticleFrontiers in pharmacology2026
FOXC1 drives lung cancer metastasis and functions as a target for AI-enabled anti-metastatic drug discovery.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer metastasis remains the leading cause of treatment failure and death. Forkhead box C1 (FOXC1) promotes cancer progression, but its definitive mechanism in lung cancer metastasis and druggable potential remain unclear. This study aimed to clarify the mechanism and develop a FOXC1-targeted inhibitor. Methods: FOXC1 expression was analyzed using the HCMDB database. Metastatic function was evaluated using migration and invasion assays and experimental pulmonary metastasis models. Dual-luciferase reporter assays and ChIP-PCR were used to characterize the FOXC1/β-catenin feedback loop. Candidate FOXC1-binding compounds were generated using the MolProphet AI platform. Binding was evaluated by SPR and MST, and complex stability was assessed by molecular docking and molecular dynamics simulations. Results: FOXC1 expression was elevated in metastatic lung cancer lesions. FOXC1 directly bound the β-catenin promoter, whereas β-catenin-activated TCF4 reciprocally stimulated FOXC1 transcription, forming a self-reinforcing positive-feedback loop. FOXC1-I4 bound FOXC1, reduced FOXC1-dependent reporter activity, and inhibited lung cancer cell migration, invasion, and early pulmonary colonization without significantly affecting cell viability at the tested concentrations. Conclusion: This study identifies a FOXC1/β-catenin positive-feedback loop that promotes lung cancer metastasis and identifies FOXC1-I4 as an AI-designed FOXC1-binding lead compound with anti-metastatic activity in the experimental models used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.